



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/921,290	08/03/2001	David M. Goldenberg	IMMU:015US	5316
37013 7590 07/24/2009 ROSSI, KIMMS & McDOWELL, LLP. 20609 Gordon Park Square, Suite 150 Ashburn, VA 20147				
EXAMINER				
HARRIS, ALANA M				
ART UNIT		PAPER NUMBER		
1643				
MAIL DATE		DELIVERY MODE		
07/24/2009		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

09/921,290

Applicant(s)

GOLDENBERG, DAVID M.

Examiner

Alana M. Harris, Ph.D.

Art Unit

1643

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 11 May 2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-10, 14-18, 25-29, 32-37, 41-48 and 52-63 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-10, 14-18, 25-29, 32-37, 41-48 and 52-63 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

Response to Amendments and Arguments

1. Claims 1-3, 5-10, 14-18, 25-29, 32-37, 41-44, 46, 48 and 52-63 are pending.

Claims 1, 9 and 54 have been amended.

Claims 4 and 49-51 have been cancelled.

Claims 57-63 have been added.

Claims 1-3, 5-10, 14-18, 25-29, 32-37, 41-44, 46, 48 and 52-63 are examined on the merits.

2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Withdrawn Grounds of Rejection

Claim Rejections - 35 USC § 102

3. The rejection of claims 1-3, 5, 8-10, 15-18, 25, 26, 32, 33, 37, 41-43, 46, 48, 54, 55 under 35 U.S.C. 102(e) as being anticipated by Hanna et al./ U.S. Patent Application Publication number 2001/0018041 A1 (filed April 16, 2001) is withdrawn in light of Applicant's amendments to the claims.

Claim Rejections - 35 USC § 103

4. The rejection of claims 1-3, 5-10, 14-18, 25-29, 32-37, 41-44, 46, 48, 50 and 52-56 are rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent Hanna et al./ Application Publication number 2001/0018041 A1 (filed April 16, 2001), and further in view of Brozek, C. M. et al. (J Clin Lab Immunol. 31(3): 105-9, March 1990), Leskovar/ U.S. Patent Application Publication number 2002/0094542 A1 (effective filing date May 3, 1999), Rybak et al. (Proc. Nat. Acad. Sci. USA 89: 3165-3169, April 1992) and Halliwell (J. Am. Vet. Med. Assoc. 181(10): 1088-96, Nov. 15, 1982) is withdrawn in light of Applicant's amendments.

New Grounds of Rejection

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. Claims 1-3, 5-10, 14-18, 25-29, 32-37, 41-44, 46, 48 and 52-63 are rejected under 35 U.S.C. 103(a) as being unpatentable over Brozek, C. M. et al. (J Clin Lab Immunol. 31(3): 105-9, March 1990), and further in view of Kvalheim (Journal of the National Cancer Institute 80(16): 1322-1325, October 19, 1988), Leskovar/ U.S. Patent Application Publication number 2002/0094542 A1 (effective filing date May 3, 1999),

Rybak et al. (Proc. Nat. Acad. Sci. USA 89: 3165-3169, April 1992), Hanna et al./ U.S. Patent Application Publication number 2001/0018041 A1 (filed April 16, 2001) and Halliwell (J. Am. Vet. Med. Assoc. 181(10): 1088-96, Nov. 15, 1982).

In anticipation of new grounds of rejection Applicant asserts in Remarks submitted May 11, 2009 Brozek does not teach anti-HLA-DR antibodies are effective to treat a B-cell disorder in animals, especially since it is clear member of the genus of anti-MHC class II antibodies behave differently in humans, see page 6, 4th paragraph. Applicant further asserts the previous publications implemented in rejections set forth in the Action mailed December 10, 2008 do not teach treatment of B cell malignancies targeting HLA-DR antigens, see bridging paragraph of pages 6 and 7 of the Remarks. These points of view have been carefully considered, but fail to persuade.

Brozek clearly teaches successful treatment with several monoclonal anti-DR antibodies to specifically inhibit the production of rheumatoid factor (RF) in rheumatoid arthritis (RA) patients, see abstract. RA is an autoimmune disease and encompassed by the broader term, B-cell disorder. While all the antibodies "under" the recitation, anti-MHC class II antibodies are not effective this does not preclude the teaching, anti-DR antibodies are effective in treating a B-cell disorder. While a statement about anti-MHC class II in animals does not equate to a teaching of anti-DR in animals, anti-Ia antibodies have been used successfully in animal models, see Brozek, bridging paragraph of columns 1 and 2 of page 105. Brozek does not teach the method wherein the therapeutic composition further comprises a cytokine, drug or toxin and the antibody component comprises a hapten with an attached therapeutic agent, as well as the

treated B-cell disorders are lymphoma, leukemia, autoimmune diseases selected from the group consisting of immune-mediated autoimmune hemolytic anemia, rheumatoid arthritis, systemic lupus erythematosus, bullous pemphigoid, pemphigus, and thrombocytopenia.

However, Kvalheim teaches implementing an anti-HLA-DR antibody in treatment with patients with non-T-cell acute lymphocytic leukemia, non-Hodgkin's lymphoma and some acute cases of acute myelogenous leukemia, see abstract. Leskovar teaches the claimed method, wherein a therapeutic composition comprising conjugates composed of antibodies, cytotoxins and cytokines capable of binding more than one antigen for the treatment of cancer, as well as autoimmune diseases, see page 3, sections 0032 and 0046; page 9, section 0131; and page 14, section 0191. The therapeutic agents can be conjugated with haptenic groups, see page 12, section 0165; page 16, section 0213; and page 18, section 0243. Rybak teaches the use of chimeric antibodies linked to toxins such as RNase to target tumor cells, see page 3165, abstract and introduction. Hanna teaches combination therapies and method of treating B-cell lymphomas and leukemias in domestic animals, see column 0082, page 7. Halliwell teaches autoimmune diseases of domestic animals, see entire document. It would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to utilize the different combinations of the therapeutic compositions for treatment of B-cell lymphomas and leukemias, including autoimmune diseases in domestic animals. It would have been *prima facie* obvious to add to the composition a RNase toxin because Brozek teaches that anti-MHC class II antibodies are useful in the

treatment of autoimmune diseases and Hannna teaches a combination of antibodies for effective treatment and the cytotoxic potential of the RNase toxin is increased and functional experiments have proven tumor growth inhibitory activity. One of ordinary skill in the art would have been motivated to manufacture such a medicament in order to effectively treat companion animals/domestic animals because all publications set forth treatment of B cell malignancies targeting the cancer antigens, see all documents in their entireties, particularly Hanna.

Conclusion

7. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

8. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Alana M. Harris, Ph.D. whose telephone number is (571)272-0831. The Examiner works a flexible schedule, however she can normally be reached Monday through Saturday on 7:30 am to 6:30 pm with alternate Fridays off.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Larry R. Helms, Ph.D. can be reached on (571) 272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Alana M. Harris, Ph.D.
20 July 2009
/Alana M. Harris, Ph.D./
Primary Examiner, Art Unit 1643